MedPath

北京四环制药有限公司

Ownership
-
Established
1995-12-26
Employees
-
Market Cap
-
Website
www.bjshengke.net

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

82

NMPA:82

Drug Approvals

Duloxetine Hydrochloride Enteric Capsules

Product Name
盐酸度洛西汀肠溶胶囊
Approval Number
国药准字H20254131
Approval Date
May 13, 2025
NMPA

Duloxetine Hydrochloride Enteric Capsules

Product Name
盐酸度洛西汀肠溶胶囊
Approval Number
国药准字H20254133
Approval Date
May 13, 2025
NMPA

Duloxetine Hydrochloride Enteric Capsules

Product Name
盐酸度洛西汀肠溶胶囊
Approval Number
国药准字H20254132
Approval Date
May 13, 2025
NMPA

Rivastigmine Hydrogen Tartrate Capsules

Product Name
重酒石酸卡巴拉汀胶囊
Approval Number
国药准字H20203011
Approval Date
Oct 16, 2024
NMPA

Rivastigmine Hydrogen Tartrate Capsules

Product Name
重酒石酸卡巴拉汀胶囊
Approval Number
国药准字H20203012
Approval Date
Oct 16, 2024
NMPA

Levetiracetam Tablets

Product Name
左乙拉西坦片
Approval Number
国药准字H20203018
Approval Date
Oct 15, 2024
NMPA

Levetiracetam Tablets

Product Name
左乙拉西坦片
Approval Number
国药准字H20203017
Approval Date
Oct 15, 2024
NMPA

Nicergoline for Injection

Product Name
注射用尼麦角林
Approval Number
国药准字H20084284
Approval Date
Aug 22, 2024
NMPA

Nicergoline for Injection

Product Name
注射用尼麦角林
Approval Number
国药准字H20084283
Approval Date
Aug 22, 2024
NMPA

Nicergoline for Injection

Product Name
注射用尼麦角林
Approval Number
国药准字H20084282
Approval Date
Aug 22, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.